Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Summary

The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Timeline

Start

2017-06-27

Primary completion

2020-06-30

Completion

2021-09-23

Publications

• Bowman SJ, Fox R, Dorner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30.

Drugs

Indications